QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo 期刊论文 BIOMEDICINE & PHARMACOTHERAPY, 2019, 卷号: 112 作者:  Xiong, Yudi;  Li, Tianqi;  Assani, Ganiou;  Ling, Huan;  Zhou, Qian 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05 Cervical cancer  CDK4  CDK6  Ribociclib  Cell cycle  Cell apoptosis   Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway 期刊论文 ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 卷号: 47, 期号: 1 作者:  Li, Tianqi;  Xiong, Yudi;  Wang, Qingqing;  Chen, Fengxia;  Zeng, Yangyang 收藏  |  浏览/下载：22/0  |  提交时间：2019/12/05 Triple-negative breast cancer  ribociclib (LEE011)  proliferation  cell cycle  apoptosis   Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo. 期刊论文 Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, 卷号: Vol.112, 页码: 108602 作者:  Yudi Xiong;  Tianqi Li;  Ganiou Assani;  Huan Ling;  Qian Zhou 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/17 CDK4  CDK6  Cell  apoptosis  Cell  cycle  Cervical  cancer  Ribociclib   乳腺癌靶向治疗新药ribociclib 期刊论文 2018, 期号: 01, 页码: 8-11 作者:  彭文绣;  杜小莉 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 ribociclib  乳腺癌  CDK4/6抑制剂   Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC): MONALEESA-7 期刊论文 Journal of Clinical Oncology, 2015, 卷号: 33 作者:  Tripathy D., Bardia A., Hurvitz S.A., Harbeck N., Colleoni M., Franke F.A., Chow L.W.C., Im S.-A., Shao Z., Keyserlingk J.R., Soler L.M., Horan M., Dhuria S.V., Hughes G., Lu Y.-S. 收藏  |  浏览/下载：12/0  |  提交时间：2019/12/19 MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC) 会议论文 作者:  Im, S. -A.;  Chow, L.;  Shao, Z.;  Tripathy, D.;  Bardia, A. 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/19 Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC): MONALEESA-7. 会议论文 作者:  Tripathy, Debu;  Bardia, Aditya;  Hurvitz, Sara A.;  Harbeck, Nadia;  Colleoni, Marco 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/19